N/A N=12,386 Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 PF-06372865 in Subjects With Photosensitive Epilepsy
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
Phase 2 N=147 A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
N/A N=281 Clinical Study With Lyrica In Patients Suffering From Epilepsy
Neuralgia · Epilepsy
Primary: Percentage of Participants With a 50 Percent or Greater Reduction From Baseline in 28 Day Partial Seizure Frequency — 85.00 Percentage of participants
Phase 2 N=7 Thalidomide Low Threshold in Epilepsy
Refractory Epilepsy
Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02
N/A N=21 Steps for Epilepsy
Epilepsy
Primary: Proportion of Participants Who Achieve Their Assigned Step Goal - Adherence — 0.267 Proportion
Phase 4 N=20 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
Epilepsy · Contraception
Primary: Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level — 0 percentage of participants
N/A N=9 Seizure Activity in Alzheimer's Disease
Alzheimer's Disease · Seizures
Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants
Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Phase 2 N=24 Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
Epilepsy
Primary: Seizure Frequency — 0.655; 0.435; 0.631 Seizures per Day
N/A N=19 Drug Exposure Registry for GSK2248761, an Investigational NNRTI
HIV Infections
Primary: Number of Participants With Occurrence of Seizure — 0; 1 Participants
Phase 3 N=130 Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Epilepsy
Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants
N/A N=140 Medication Adherence in Individuals With Epilepsy
Epilepsy
Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days
N/A N=199 Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
Epilepsy
Primary: Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency — 138; 44; 17 participants
Phase 4 N=69 Anxiety and Depression in Epilepsy: A Treatment Study
Anxiety · Depression · Epilepsy
Primary: Adherence to Intervention — 2; 0; 0 Participants
Phase 3 N=44 An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures
Epilepsy · Generalized Tonic-clonic Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period — 626 Treatment Emergent Adverse Events
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
Phase 3 N=109 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
Phase 4 N=103 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Phase 2 N=125 Anti-epileptogenic Effects of Eslicarbazepine Acetate
Post Stroke Epilepsy
Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants
Phase 2 N=11 Pilot Study of Melatonin and Epilepsy
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Phase 3 N=172 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
Epilepsy
Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.156; 0.128 proportion of participants
N/A N=80 Premenstrual Dysphoric Disorder and Antiepileptic Drugs
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
Phase 3 N=71 An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
Epilepsy · Partial Onset Seizures
Primary: Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation…
Phase 3 N=193 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Epilepsy With Simple or Complex Partial Onset Seizures
Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.444; 0.287 proportion of participants
Phase 2 N=84 Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Phase 2 N=24 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Phase 3 N=853 Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
Epilepsy
Primary: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 84.4 Percentage of participants
N/A N=31 Seizure Detection and Automatic Magnet Mode Performance Study
Epilepsy
Primary: Summary of Seizures Reported by Investigators and Triple Review — 87; 124; 211; 82 Seizures
Phase 3 N=100 Randomized Therapy In Status Epilepticus
Status Epilepticus
Primary: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE — 79.59…